BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bosch-barrera J, Queralt B, Menendez JA. Targeting STAT3 with silibinin to improve cancer therapeutics. Cancer Treatment Reviews 2017;58:61-9. [DOI: 10.1016/j.ctrv.2017.06.003] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 9.8] [Reference Citation Analysis]
Number Citing Articles
1 Lu C, Lei W, Sun M, Wu X, Liu Q, Liu J, Yang Y, Yang W, Zhang Z, Li X, Zhou Y, Deng C, Chen Y, Tian Y, Yang Y. Identification of CCR2 as a hub in septic myocardial injury and cardioprotection of silibinin. Free Radic Biol Med 2023:S0891-5849(23)00031-X. [PMID: 36693441 DOI: 10.1016/j.freeradbiomed.2023.01.020] [Reference Citation Analysis]
2 Verdura S, Encinar JA, Teixidor E, Segura-Carretero A, Micol V, Cuyàs E, Bosch-Barrera J, Menendez JA. Silibinin Overcomes EMT-Driven Lung Cancer Resistance to New-Generation ALK Inhibitors. Cancers (Basel) 2022;14. [PMID: 36551587 DOI: 10.3390/cancers14246101] [Reference Citation Analysis]
3 Jafari S, Bakhshaei A, Eskandani M, Molavi O. Silibinin-Loaded Nanostructured Lipid Carriers for Growth Inhibition of Cisplatin-Resistant Ovarian Cancer Cells. ASSAY and Drug Development Technologies 2022. [DOI: 10.1089/adt.2022.060] [Reference Citation Analysis]
4 Zhang Y, Chen Y, Chen C, Guo H, Zhou C, Wang H, Liu Z. PITX1 suppresses osteosarcoma metastasis through exosomal LINC00662-mediated M2 macrophage polarization. Clin Exp Metastasis 2022. [DOI: 10.1007/s10585-022-10192-5] [Reference Citation Analysis]
5 Romani AM. Cisplatin in Cancer Treatment. Biochemical Pharmacology 2022. [DOI: 10.1016/j.bcp.2022.115323] [Reference Citation Analysis]
6 Tiwari P, Mishra KP. Role of Plant-Derived Flavonoids in Cancer Treatment. Nutr Cancer 2022;:1-20. [PMID: 36264133 DOI: 10.1080/01635581.2022.2135744] [Reference Citation Analysis]
7 Falconi García MA, Guevara Betancur JE. A propósito de un caso: uso de la silimarina/silibinina como análogo molecular del remdesivir para el tratamiento de pacientes diagnosticados de COVID-19 con síndrome de dificultad respiratoria aguda leve o moderado. Reporte de caso. Rev Cient 2022;30. [DOI: 10.54495/rev.cientifica.v30i2.286] [Reference Citation Analysis]
8 Wadhwa K, Pahwa R, Kumar M, Kumar S, Sharma PC, Singh G, Verma R, Mittal V, Singh I, Kaushik D, Jeandet P. Mechanistic Insights into the Pharmacological Significance of Silymarin. Molecules 2022;27:5327. [PMID: 36014565 DOI: 10.3390/molecules27165327] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Yang J, Wang L, Guan X, Qin JJ. Inhibiting STAT3 signaling pathway by natural products for cancer prevention and therapy: In vitro and in vivo activity and mechanisms of action. Pharmacol Res 2022;182:106357. [PMID: 35868477 DOI: 10.1016/j.phrs.2022.106357] [Reference Citation Analysis]
10 Li H, Cai M, Cao F, Yu D, Yang J, Yu W, chu C, Guan X, Qin J, Dong J. S3I-201 derivative incorporating naphthoquinone unit as effective STAT3 inhibitors:design, synthesis and anti-gastric cancer evaluation. Bioorganic & Medicinal Chemistry 2022. [DOI: 10.1016/j.bmc.2022.116941] [Reference Citation Analysis]
11 Bai Y, Chen J, Hu W, Wang L, Wu Y, Yu S. Silibinin Therapy Improves Cholangiocarcinoma Outcomes by Regulating ERK/Mitochondrial Pathway. Front Pharmacol 2022;13:847905. [DOI: 10.3389/fphar.2022.847905] [Reference Citation Analysis]
12 Wang H, Man Q, Huo F, Gao X, Lin H, Li S, Wang J, Su F, Cai, L, Shi Y, Liu, B, Bu L. STAT3 pathway in cancers: Past, present, and future. MedComm 2022;3. [DOI: 10.1002/mco2.124] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
13 Letafati A, Najafi S, Mottahedi M, Karimzadeh M, Shahini A, Garousi S, Abbasi-Kolli M, Sadri Nahand J, Tamehri Zadeh SS, Hamblin MR, Rahimian N, Taghizadieh M, Mirzaei H. MicroRNA let-7 and viral infections: focus on mechanisms of action. Cell Mol Biol Lett 2022;27:14. [PMID: 35164678 DOI: 10.1186/s11658-022-00317-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 18.0] [Reference Citation Analysis]
14 Koltai T, Fliegel L. Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions. J Evid Based Integr Med 2022;27:2515690X211068826. [PMID: 35018864 DOI: 10.1177/2515690X211068826] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Bosch-Barrera J, Roqué A, Teixidor E, Carmona-Garcia MC, Arbusà A, Brunet J, Martin-Castillo B, Cuyàs E, Verdura S, Menendez JA. Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin. Pharmaceuticals (Basel) 2021;15:19. [PMID: 35056076 DOI: 10.3390/ph15010019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Li M, Chen C, Wang Q, Jiang X, Tan L, Huang Y, Zhang Y, Zhang Z. Glaucocalyxin A suppresses multiple myeloma progression in vitro and in vivo through inhibiting the activation of STAT3 signaling pathway. Cancer Cell Int 2021;21:683. [PMID: 34923957 DOI: 10.1186/s12935-021-02375-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Kaçar S, Bektur Aykanat NE. SİLİMARİN, SLIT2 PROTEİNİNİ AKTİVE EDEREK VE CXCR4 EKSPRESYONUNU BASKILAYARAK A549 HÜCRELERİNİ İNHİBE ETTİ. Uludağ Üniversitesi Tıp Fakültesi Dergisi 2021. [DOI: 10.32708/uutfd.971366] [Reference Citation Analysis]
18 Qin Z, Tong H, Li T, Cao H, Zhu J, Yin S, He W. SPHK1 contributes to cisplatin resistance in bladder cancer cells via the NONO/STAT3 axis. Int J Mol Med 2021;48:204. [PMID: 34549307 DOI: 10.3892/ijmm.2021.5037] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Yin Q, Wang L, Yu H, Chen D, Zhu W, Sun C. Pharmacological Effects of Polyphenol Phytochemicals on the JAK-STAT Signaling Pathway. Front Pharmacol 2021;12:716672. [PMID: 34539403 DOI: 10.3389/fphar.2021.716672] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
20 Bosch-Barrera J, Verdura S, Ruffinelli JC, Carcereny E, Sais E, Cuyàs E, Palmero R, Lopez-Bonet E, Hernández-Martínez A, Oliveras G, Buxó M, Izquierdo A, Morán T, Nadal E, Menendez JA. Silibinin Suppresses Tumor Cell-Intrinsic Resistance to Nintedanib and Enhances Its Clinical Activity in Lung Cancer. Cancers (Basel) 2021;13:4168. [PMID: 34439322 DOI: 10.3390/cancers13164168] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
21 Chavoshy F, Zadeh BSM, Tamaddon AM, Anbardar MH. Delivery and Anti-Psoriatic Effect of Silibinin-Loaded Polymeric Micelles: An Experimental Study in the Psoriatic Skin Model. Curr Drug Deliv 2020;17:787-98. [PMID: 32703129 DOI: 10.2174/1567201817666200722141807] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
22 Man S, Luo C, Yan M, Zhao G, Ma L, Gao W. Treatment for liver cancer: From sorafenib to natural products. Eur J Med Chem 2021;224:113690. [PMID: 34256124 DOI: 10.1016/j.ejmech.2021.113690] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
23 Verdura S, Cuyàs E, Ruiz-Torres V, Micol V, Joven J, Bosch-Barrera J, Menendez JA. Lung Cancer Management with Silibinin: A Historical and Translational Perspective. Pharmaceuticals (Basel) 2021;14:559. [PMID: 34208282 DOI: 10.3390/ph14060559] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
24 Velmurugan BK, Lin JT, Mahalakshmi B, Lin CC, Chuang YC, Lo YS, Ho HY, Hsieh MJ, Chen MK. Dehydrocrenatidine inhibits head and neck cancer cells invasion and migration by modulating JNK1/2 and ERK1/2 pathway and decreases MMP-2 expression. Environ Toxicol 2021;36:1848-56. [PMID: 34076342 DOI: 10.1002/tox.23305] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Binienda A, Ziolkowska S, Pluciennik E. The Anticancer Properties of Silibinin: Its Molecular Mechanism and Therapeutic Effect in Breast Cancer. Anticancer Agents Med Chem 2020;20:1787-96. [PMID: 31858905 DOI: 10.2174/1871520620666191220142741] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
26 Gao J, Hou D, Hu P, Mao G. Curcumol increases the sensitivity of colon cancer to 5-FU by regulating Wnt/β-catenin signaling. Transl Cancer Res 2021;10:2437-50. [PMID: 35116559 DOI: 10.21037/tcr-21-689] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
27 Guo S, Bai X, Liu Y, Shi S, Wang X, Zhan Y, Kang X, Chen Y, An H. Inhibition of TMEM16A by Natural Product Silibinin: Potential Lead Compounds for Treatment of Lung Adenocarcinoma. Front Pharmacol 2021;12:643489. [PMID: 33935737 DOI: 10.3389/fphar.2021.643489] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
28 Santoni M, Miccini F, Cimadamore A, Piva F, Massari F, Cheng L, Lopez-Beltran A, Montironi R, Battelli N. An update on investigational therapies that target STAT3 for the treatment of cancer. Expert Opin Investig Drugs 2021;30:245-51. [PMID: 33599169 DOI: 10.1080/13543784.2021.1891222] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
29 Liang H, Xu M, Xiong Z, Hu K, Yang J, Cao M, Zhong Z, Yao Z, Deng M, Liu B. Identification of miRNAs as diagnostic and prognostic markers in hepatocellular carcinoma. Aging (Albany NY) 2021;13:6115-33. [PMID: 33617479 DOI: 10.18632/aging.202606] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
30 Aziz MA, Sarwar MS, Akter T, Uddin MS, Xun S, Zhu Y, Islam MS, Hongjie Z. Polyphenolic molecules targeting STAT3 pathway for the treatment of cancer. Life Sci 2021;268:118999. [PMID: 33421525 DOI: 10.1016/j.lfs.2020.118999] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
31 Siddiqui N, Abidin L, Nisar N, Ahmad I, Siddiqui AN. Flavonoids Targeting Cancer Stem Cells: A Paradigm to Anticancer Efficacy. Polyphenols-based Nanotherapeutics for Cancer Management 2021. [DOI: 10.1007/978-981-16-4935-6_7] [Reference Citation Analysis]
32 Zhu J, Wang J, Huang J, Du W, He Y, Pan H, Luo J. MicroRNA-140-5p regulates the proliferation, apoptosis and inflammation of RA FLSs by repressing STAT3. Exp Ther Med 2021;21:171. [PMID: 33456538 DOI: 10.3892/etm.2020.9602] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
33 Kaipa JM, Starkuviene V, Erfle H, Eils R, Gladilin E. Transcriptome profiling reveals Silibinin dose-dependent response network in non-small lung cancer cells. PeerJ 2020;8:e10373. [PMID: 33362957 DOI: 10.7717/peerj.10373] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
34 Wang X, Zhang Z, Wu SC. Health Benefits of Silybum marianum: Phytochemistry, Pharmacology, and Applications. J Agric Food Chem 2020;68:11644-64. [PMID: 33045827 DOI: 10.1021/acs.jafc.0c04791] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 7.7] [Reference Citation Analysis]
35 Mashhadi Akbar Boojar M, Mashhadi Akbar Boojar M, Golmohammad S. Overview of Silibinin anti-tumor effects. Journal of Herbal Medicine 2020;23:100375. [DOI: 10.1016/j.hermed.2020.100375] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
36 Tsaroucha AK, Korovesis GN, Valsami G, Lambropoulou M, Kollaras V, Anagnostopoulos C, Kostomitsopoulos N, Zerbini E, Simopoulos C. Silibinin-hydroxypropyl-β-cyclodextrin (SLB-HP-β-CD) complex prevents apoptosis in liver and kidney after hepatic ischemia-reperfusion injury. Food Chem Toxicol 2020;145:111731. [PMID: 32891719 DOI: 10.1016/j.fct.2020.111731] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
37 Tse C, Warner A, Farook R, Cronin JG. Phytochemical Targeting of STAT3 Orchestrated Lipid Metabolism in Therapy-Resistant Cancers. Biomolecules 2020;10:E1118. [PMID: 32731620 DOI: 10.3390/biom10081118] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
38 Li M, Meng X, Li M. MiR-126 promotes esophageal squamous cell carcinoma via inhibition of apoptosis and autophagy. Aging (Albany NY) 2020;12:12107-18. [PMID: 32554852 DOI: 10.18632/aging.103379] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
39 Gonzalez-Mancera MS, Johnson B, Mirsaeidi M. STAT3 gain-of-function mutation in a patient with pulmonary Mycobacterium abscessus infection. Respir Med Case Rep 2020;30:101125. [PMID: 32577366 DOI: 10.1016/j.rmcr.2020.101125] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
40 Bose S, Banerjee S, Mondal A, Chakraborty U, Pumarol J, Croley CR, Bishayee A. Targeting the JAK/STAT Signaling Pathway Using Phytocompounds for Cancer Prevention and Therapy. Cells 2020;9:E1451. [PMID: 32545187 DOI: 10.3390/cells9061451] [Cited by in Crossref: 60] [Cited by in F6Publishing: 65] [Article Influence: 20.0] [Reference Citation Analysis]
41 Bosch-Barrera J, Martin-Castillo B, Buxó M, Brunet J, Encinar JA, Menendez JA. Silibinin and SARS-CoV-2: Dual Targeting of Host Cytokine Storm and Virus Replication Machinery for Clinical Management of COVID-19 Patients. J Clin Med 2020;9:E1770. [PMID: 32517353 DOI: 10.3390/jcm9061770] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 9.7] [Reference Citation Analysis]
42 Zhang T, He L, Wang Z, Dong W, Sun W, Qin Y, Zhang P, Zhang H. Calcitriol enhances Doxorubicin-induced apoptosis in papillary thyroid carcinoma cells via regulating VDR/PTPN2/p-STAT3 pathway. J Cell Mol Med 2020;24:5629-39. [PMID: 32285621 DOI: 10.1111/jcmm.15224] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
43 Shen Y, Zhao H, Wang Z, Guan W, Kang X, Tai X, Sun Y. Silibinin declines blue light-induced apoptosis and inflammation through MEK/ERK/CREB of retinal ganglion cells. Artif Cells Nanomed Biotechnol 2019;47:4059-65. [PMID: 31631701 DOI: 10.1080/21691401.2019.1671430] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
44 You Y, He Q, Lu H, Zhou X, Chen L, Liu H, Lu Z, Liu D, Liu Y, Zuo D, Fu X, Kwan H, Zhao X. Silibinin Induces G2/M Cell Cycle Arrest by Activating Drp1-Dependent Mitochondrial Fission in Cervical Cancer. Front Pharmacol 2020;11:271. [PMID: 32226384 DOI: 10.3389/fphar.2020.00271] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
45 Zeng C, Fan D, Xu Y, Li X, Yuan J, Yang Q, Zhou X, Lu J, Zhang C, Han J, Gu J, Gao Y, Sun L, Wang S. Curcumol enhances the sensitivity of doxorubicin in triple-negative breast cancer via regulating the miR-181b-2-3p-ABCC3 axis. Biochem Pharmacol 2020;174:113795. [PMID: 31926937 DOI: 10.1016/j.bcp.2020.113795] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 9.7] [Reference Citation Analysis]
46 Yang L, Lin S, Xu L, Lin J, Zhao C, Huang X. Novel activators and small-molecule inhibitors of STAT3 in cancer. Cytokine Growth Factor Rev 2019;49:10-22. [PMID: 31677966 DOI: 10.1016/j.cytogfr.2019.10.005] [Cited by in Crossref: 59] [Cited by in F6Publishing: 63] [Article Influence: 14.8] [Reference Citation Analysis]
47 Cuyàs E, Verdura S, Micol V, Joven J, Bosch-barrera J, Encinar JA, Menendez JA. Revisiting silibinin as a novobiocin-like Hsp90 C-terminal inhibitor: Computational modeling and experimental validation. Food and Chemical Toxicology 2019;132:110645. [DOI: 10.1016/j.fct.2019.110645] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
48 Zhu B, Ren C, Du K, Zhu H, Ai Y, Kang F, Luo Y, Liu W, Wang L, Xu Y, Jiang X, Zhang Y. Olean-28,13b-olide 2 plays a role in cisplatin-mediated apoptosis and reverses cisplatin resistance in human lung cancer through multiple signaling pathways. Biochem Pharmacol 2019;170:113642. [PMID: 31541631 DOI: 10.1016/j.bcp.2019.113642] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
49 Sun C, Nie J, Huang J, Zheng G, Feng B. Targeting STAT3 inhibition to reverse cisplatin resistance. Biomedicine & Pharmacotherapy 2019;117:109135. [DOI: 10.1016/j.biopha.2019.109135] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 8.0] [Reference Citation Analysis]
50 Chirshev E, Oberg KC, Ioffe YJ, Unternaehrer JJ. Let-7 as biomarker, prognostic indicator, and therapy for precision medicine in cancer. Clin Transl Med 2019;8:24. [PMID: 31468250 DOI: 10.1186/s40169-019-0240-y] [Cited by in Crossref: 108] [Cited by in F6Publishing: 112] [Article Influence: 27.0] [Reference Citation Analysis]
51 Wei L, Wang Z, Xia Y, Liu B. The mechanism and tumor inhibitory study of Lagopsis supine ethanol extract on colorectal cancer in nude mice. BMC Complement Altern Med 2019;19:173. [PMID: 31299960 DOI: 10.1186/s12906-019-2585-6] [Reference Citation Analysis]
52 Sherman B, Hernandez AM, Alhado M, Menge L, Price RS. Silibinin Differentially Decreases the Aggressive Cancer Phenotype in an In Vitro Model of Obesity and Prostate Cancer. Nutr Cancer 2020;72:333-42. [PMID: 31287731 DOI: 10.1080/01635581.2019.1633363] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
53 Xia L, Wu L, Xia H, Bao J, Li Q, Chen X, Xia R. miR-337 suppresses cutaneous T-cell lymphoma via the STAT3 pathway. Cell Cycle 2019;18:1635-45. [PMID: 31213131 DOI: 10.1080/15384101.2019.1629789] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
54 Li W, Zhao X, Lv X, Han W, Wang H. Silibinin Retards Colitis-associated Carcinogenesis by Repression of Cdc25C in Mouse Model. Inflamm Bowel Dis 2019;25:1187-95. [PMID: 30753481 DOI: 10.1093/ibd/izz007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
55 Pérez-Sánchez A, Cuyàs E, Ruiz-Torres V, Agulló-Chazarra L, Verdura S, González-Álvarez I, Bermejo M, Joven J, Micol V, Bosch-Barrera J, Menendez JA. Intestinal Permeability Study of Clinically Relevant Formulations of Silibinin in Caco-2 Cell Monolayers. Int J Mol Sci 2019;20:E1606. [PMID: 30935093 DOI: 10.3390/ijms20071606] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
56 Wang C, Wang Z, Liu W, Ai Z. ROS-generating oxidase NOX1 promotes the self-renewal activity of CD133+ thyroid cancer cells through activation of the Akt signaling. Cancer Lett 2019;447:154-63. [PMID: 30690057 DOI: 10.1016/j.canlet.2019.01.028] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
57 Shi Z, Zhou Q, Gao S, Li W, Li X, Liu Z, Jin P, Jiang J. Silibinin inhibits endometrial carcinoma via blocking pathways of STAT3 activation and SREBP1-mediated lipid accumulation. Life Sciences 2019;217:70-80. [DOI: 10.1016/j.lfs.2018.11.037] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
58 Ullah MF, Bhat SH, Abu-duhier FM. Nutraceuticals and Natural Product Derivatives in the Premises of Disease Prevention. Nutraceuticals and Natural Product Derivatives 2018. [DOI: 10.1002/9781119436713.ch5] [Reference Citation Analysis]
59 Dai X, Geng F, Dai J, Li M, Liu M. Rho GTPase Activating Protein 24 (ARHGAP24) Regulates the Anti-Cancer Activity of Sorafenib Against Breast Cancer MDA-MB-231 Cells via the Signal Transducer and Activator of Transcription 3 (STAT3) Signaling Pathway. Med Sci Monit 2018;24:8669-77. [PMID: 30499465 DOI: 10.12659/MSM.911394] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
60 Jahanafrooz Z, Motamed N, Rinner B, Mokhtarzadeh A, Baradaran B. Silibinin to improve cancer therapeutic, as an apoptotic inducer, autophagy modulator, cell cycle inhibitor, and microRNAs regulator. Life Sci 2018;213:236-47. [PMID: 30308184 DOI: 10.1016/j.lfs.2018.10.009] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 8.8] [Reference Citation Analysis]
61 Abenavoli L, Izzo AA, Milić N, Cicala C, Santini A, Capasso R. Milk thistle (Silybum marianum): A concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases. Phytother Res 2018;32:2202-13. [PMID: 30080294 DOI: 10.1002/ptr.6171] [Cited by in Crossref: 174] [Cited by in F6Publishing: 183] [Article Influence: 34.8] [Reference Citation Analysis]
62 Li X, Zhao Z, Li M, Liu M, Bahena A, Zhang Y, Zhang Y, Nambiar C, Liu G. Sulforaphane promotes apoptosis, and inhibits proliferation and self-renewal of nasopharyngeal cancer cells by targeting STAT signal through miRNA-124-3p. Biomedicine & Pharmacotherapy 2018;103:473-81. [DOI: 10.1016/j.biopha.2018.03.121] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
63 Won D, Kim L, Jang B, Yang I, Kwon H, Jin B, Oh SH, Kang J, Hong S, Shin J, Cho S. In vitro and in vivo anti-cancer activity of silymarin on oral cancer. Tumour Biol 2018;40:101042831877617. [DOI: 10.1177/1010428318776170] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
64 Song D, Cao Z, Tickner J, Qiu H, Wang C, Chen K, Wang Z, Guo C, Dong S, Xu J. Poria cocos polysaccharide attenuates RANKL-induced osteoclastogenesis by suppressing NFATc1 activity and phosphorylation of ERK and STAT3. Arch Biochem Biophys 2018;647:76-83. [PMID: 29678628 DOI: 10.1016/j.abb.2018.04.011] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
65 Verdura S, Cuyàs E, Llorach-Parés L, Pérez-Sánchez A, Micol V, Nonell-Canals A, Joven J, Valiente M, Sánchez-Martínez M, Bosch-Barrera J, Menendez JA. Silibinin is a direct inhibitor of STAT3. Food Chem Toxicol 2018;116:161-72. [PMID: 29660364 DOI: 10.1016/j.fct.2018.04.028] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 8.0] [Reference Citation Analysis]
66 Prabhu KS, Achkar IW, Kuttikrishnan S, Akhtar S, Khan AQ, Siveen KS, Uddin S. Embelin: a benzoquinone possesses therapeutic potential for the treatment of human cancer. Future Medicinal Chemistry 2018;10:961-76. [DOI: 10.4155/fmc-2017-0198] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
67 Liu J, Fei D, Xing J, Du J. MicroRNA-29a inhibits proliferation and induces apoptosis in rheumatoid arthritis fibroblast-like synoviocytes by repressing STAT3. Biomed Pharmacother 2017;96:173-81. [PMID: 28987940 DOI: 10.1016/j.biopha.2017.09.120] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 6.7] [Reference Citation Analysis]